ArticleScientific reports2025
Mechanistic insights into the P-coumaric acid protection against bisphenol A-induced hepatotoxicity in in vivo and in silico models.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development of Wedelia (Current issues in molecular biology · 2026Article
- Hepatoprotective Potential of Eugenol Against Pesticide Glyphosate-Induced Liver Injury via Nrf2/HO-1 Signaling and Modulation of Apoptosis and Inflammation in Rats.Journal of biochemical and molecular toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bisphenol A (BPA), commonly found in plastic containers and epoxy resins used for food products, presents substantial health risks, particularly in relation to hepatic toxicity. This study investigates BPA-induced liver damage and explores the mechanistic dose-dependent protective effects of P-coumaric acid (PCA). 50 male rats were divided into control, BPA-treated, BPA + PCA50, BPA + PCA100, and PCA100 groups. BPA exposure for 14 days induced oxidative stress, evidenced by elevated malondialdehyde levels and decreased activities of antioxidant enzymes (superoxide dismutase, glutathione peroxidase, and catalase). Higher doses of PCA effectively mitigated these effects by restoring redox balance and enhancing antioxidant enzyme activities. Additionally, BPA disrupted inflammation and apoptosis pathways, inhibiting anti-inflammatory markers and interfering with the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 (Nrf2/HO-1) pathway. PCA exhibited dose-dependent protection against these disruptions. Computational analyses revealed that BPA inhibits cyclooxygenase-1 through stable hydrogen bonding with threonine at position 322. PCA's dual protective effect was confirmed by attenuating inflammatory pathways, including TNF-α inhibition and suppression of the Kelch-like ECH-associated protein 1 (KEAP1) and Nrf2 signaling pathway. Histopathological assessments confirmed that PCA alleviated significant hepatic damage induced by BPA. Immunohistochemical and immunofluorescence analyses further supported PCA's protective role against BPA-induced apoptosis and cellular hepatotoxicity. These findings underscore PCA's protective potential against BPA-induced hepatotoxicity and highlight novel mechanistic interactions that warrant further investigation in applied nutritional biochemistry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.